There's an enormous amount of literature and commentary out there about the tendency for federal regulators in general, and the FDA especially, to minimize "Type I" error (approving drugs that are unsafe/ineffective) with the negative consequence of making more "Type II" errors (not approving drugs that are safe and effective).